Published in FASEB J on August 03, 2010
Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Mol Cell (2011) 2.35
Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal (2014) 1.20
Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies. J Biol Chem (2011) 1.08
EGF receptor exposed to oxidative stress acquires abnormal phosphorylation and aberrant activated conformation that impairs canonical dimerization. PLoS One (2011) 1.07
erbB3 is an active tyrosine kinase capable of homo- and heterointeractions. Mol Cell Biol (2013) 1.02
Exploring higher-order EGFR oligomerisation and phosphorylation--a combined experimental and theoretical approach. Mol Biosyst (2013) 0.96
The membrane-proximal intracellular domain of the epidermal growth factor receptor underlies negative cooperativity in ligand binding. J Biol Chem (2011) 0.95
Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with ¹²⁵I-EGF. PLoS One (2011) 0.93
Lung injury and lung cancer caused by cigarette smoke-induced oxidative stress: Molecular mechanisms and therapeutic opportunities involving the ceramide-generating machinery and epidermal growth factor receptor. Antioxid Redox Signal (2014) 0.89
Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence. Am J Cancer Res (2015) 0.88
Engineered bivalent ligands to bias ErbB receptor-mediated signaling and phenotypes. J Biol Chem (2011) 0.88
Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging. J Biol Chem (2013) 0.87
Analysis of the Role of the C-Terminal Tail in the Regulation of the Epidermal Growth Factor Receptor. Mol Cell Biol (2015) 0.87
EGFR: tale of the C-terminal tail. Protein Sci (2013) 0.80
Effect of phosphorylation on EGFR dimer stability probed by single-molecule dynamics and FRET/FLIM. Biophys J (2015) 0.79
HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status. Oncotarget (2016) 0.77
The Arabidopsis thaliana SERK1 kinase domain spontaneously refolds to an active state in vitro. PLoS One (2012) 0.76
Integrated analysis reveals that STAT3 is central to the crosstalk between HER/ErbB receptor signaling pathways in human mammary epithelial cells. Mol Biosyst (2014) 0.76
A point mutation in the extracellular domain of KIT promotes tumorigenesis of mast cells via ligand-independent auto-dimerization. Sci Rep (2015) 0.75
Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 28.05
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell (2006) 10.28
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science (2000) 9.29
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res (2004) 6.53
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell (2007) 5.95
Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell (2002) 5.64
Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem (2002) 5.63
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell (2003) 5.06
Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell (2002) 4.92
Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res (2000) 4.79
Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell (2009) 4.78
Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci U S A (1994) 4.51
A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol (1996) 4.47
ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol (2009) 4.40
Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J (1996) 4.26
Targeting tyrosine kinases in cancer: the second wave. Science (2006) 3.52
Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J (1994) 3.42
The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell (2003) 3.20
Structure of the extracellular region of HER3 reveals an interdomain tether. Science (2002) 3.19
Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. Proc Natl Acad Sci U S A (1990) 3.11
The juxtamembrane region of the EGF receptor functions as an activation domain. Mol Cell (2009) 2.90
ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci U S A (2010) 2.85
The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol (2007) 2.74
Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc Natl Acad Sci U S A (2009) 2.55
Multiphoton-FLIM quantification of the EGFP-mRFP1 FRET pair for localization of membrane receptor-kinase interactions. Biophys J (2004) 2.37
EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer (2001) 1.97
Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling. Mol Biol Cell (2002) 1.95
Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. Biochem J (1997) 1.91
The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand. Proc Natl Acad Sci U S A (2005) 1.84
ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. FEBS Lett (2004) 1.79
Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. Proc Natl Acad Sci U S A (2003) 1.54
Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site. J Biol Chem (1997) 1.38
Activated ezrin promotes cell migration through recruitment of the GEF Dbl to lipid rafts and preferential downstream activation of Cdc42. Mol Biol Cell (2007) 1.36
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806. J Biol Chem (2006) 1.30
A putative mechanism for downregulation of the catalytic activity of the EGF receptor via direct contact between its kinase and C-terminal domains. Structure (2004) 1.24
Heregulin reverses the oligomerization of HER3. Biochemistry (2000) 1.20
Ligand-independent oncogenic signaling by the epidermal growth factor receptor: v-ErbB as a paradigm. Exp Cell Res (2003) 1.19
Dynamic equilibrium between multiple active and inactive conformations explains regulation and oncogenic mutations in ErbB receptors. Biochim Biophys Acta (2007) 1.10
The ErbB kinase domain: structural perspectives into kinase activation and inhibition. Exp Cell Res (2008) 1.08
Integrating receptor signal inputs that influence small Rho GTPase activation dynamics at the immunological synapse. Mol Cell Biol (2009) 1.05
The Asn418-linked N-glycan of ErbB3 plays a crucial role in preventing spontaneous heterodimerization and tumor promotion. Cancer Res (2007) 0.93
Treatment of metastatic ErbB2-positive breast cancer: options after progression on trastuzumab. Clin Breast Cancer (2008) 0.80
EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol (2006) 10.39
A module of negative feedback regulators defines growth factor signaling. Nat Genet (2007) 4.35
Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer (2008) 4.25
The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. Nature (2009) 3.62
Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol (2011) 3.52
Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene (2004) 3.27
The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res (2003) 3.18
Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell (2009) 3.18
A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration. Nat Cell Biol (2007) 2.85
The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer (2012) 2.79
Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. J Biol Chem (2003) 2.77
The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol (2007) 2.74
RhoA and RhoC have distinct roles in migration and invasion by acting through different targets. J Cell Biol (2011) 2.59
A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. EMBO J (2002) 2.42
Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys (2004) 2.41
Multiphoton-FLIM quantification of the EGFP-mRFP1 FRET pair for localization of membrane receptor-kinase interactions. Biophys J (2004) 2.37
p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy. EMBO J (2006) 2.23
LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J (2004) 2.20
Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J (2002) 2.17
EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors. Sci Signal (2010) 2.16
Hsp90 recognizes a common surface on client kinases. J Biol Chem (2006) 2.12
Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci U S A (2005) 2.00
Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta (2007) 1.97
A novel PKC-regulated mechanism controls CD44 ezrin association and directional cell motility. Nat Cell Biol (2002) 1.94
Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals. Mol Cell (2011) 1.89
Silencing of EphA3 through a cis interaction with ephrinA5. Nat Neurosci (2006) 1.86
Tal, a Tsg101-specific E3 ubiquitin ligase, regulates receptor endocytosis and retrovirus budding. Genes Dev (2004) 1.73
Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc Natl Acad Sci U S A (2009) 1.71
E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res (2007) 1.70
The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle (2004) 1.54
Sprouty fine-tunes EGF signaling through interlinked positive and negative feedback loops. Curr Biol (2003) 1.50
Roles for growth factors in cancer progression. Physiology (Bethesda) (2010) 1.48
Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. EMBO Rep (2004) 1.46
Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci U S A (2010) 1.46
Interaction of fascin and protein kinase Calpha: a novel intersection in cell adhesion and motility. EMBO J (2003) 1.45
Src promotes destruction of c-Cbl: implications for oncogenic synergy between Src and growth factor receptors. Proc Natl Acad Sci U S A (2003) 1.44
Conjugation to Nedd8 instigates ubiquitylation and down-regulation of activated receptor tyrosine kinases. J Biol Chem (2006) 1.42
Endocytosis and cancer. Cold Spring Harb Perspect Biol (2013) 1.40
Regulation of protein tyrosine phosphatase 1B by sumoylation. Nat Cell Biol (2006) 1.40
Activated ezrin promotes cell migration through recruitment of the GEF Dbl to lipid rafts and preferential downstream activation of Cdc42. Mol Biol Cell (2007) 1.36
SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents. J Biomol Screen (2006) 1.36
Coordinated RhoA signaling at the leading edge and uropod is required for T cell transendothelial migration. J Cell Biol (2010) 1.35
Site-directed perturbation of protein kinase C- integrin interaction blocks carcinoma cell chemotaxis. Mol Cell Biol (2002) 1.35
Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. FEBS Lett (2010) 1.30
Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling. J Biol Chem (2004) 1.30
An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis. Curr Biol (2009) 1.30
Systems biology of growth factor-induced receptor endocytosis. Traffic (2008) 1.26
Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. Mol Syst Biol (2007) 1.25
Spatially distinct binding of Cdc42 to PAK1 and N-WASP in breast carcinoma cells. Mol Cell Biol (2005) 1.21
Reduced proliferation and enhanced migration: two sides of the same coin? Molecular mechanisms of metastatic progression by YB-1. Cell Cycle (2009) 1.21
Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal (2014) 1.20
ErbB signaling regulates lineage determination of developing pancreatic islet cells in embryonic organ culture. Endocrinology (2002) 1.19
Imaging proteins in vivo using fluorescence lifetime microscopy. Mol Biosyst (2007) 1.19
Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proc Natl Acad Sci U S A (2007) 1.18
Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, Raf-1, and Akt. Cancer Res (2010) 1.17
EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF. FASEB J (2011) 1.17
miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours. EMBO Mol Med (2012) 1.14
Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity. J Biol Chem (2004) 1.14
Coupled pre-mRNA and mRNA dynamics unveil operational strategies underlying transcriptional responses to stimuli. Mol Syst Biol (2011) 1.13
Molecular characterization of the 2011 Hong Kong scarlet fever outbreak. J Infect Dis (2012) 1.13
Oncogenic growth factor receptors: implications for signal transduction therapy. Semin Cancer Biol (2004) 1.11
The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients. Target Oncol (2009) 1.10
Polar expression of ErbB-2/HER2 in epithelia. Bimodal regulation by Lin-7. Dev Cell (2003) 1.07
Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunol Lett (2005) 1.06
Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth. Proc Natl Acad Sci U S A (2013) 1.06
Integrating receptor signal inputs that influence small Rho GTPase activation dynamics at the immunological synapse. Mol Cell Biol (2009) 1.05
A targeted siRNA screen identifies regulators of Cdc42 activity at the natural killer cell immunological synapse. Sci Signal (2011) 1.05
Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR. Proc Natl Acad Sci U S A (2013) 1.05
ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapy. Int J Cancer (2006) 1.05
Genomic amplicons target vesicle recycling in breast cancer. J Clin Invest (2009) 1.04
Regulation of signalling by microRNAs. Biochem Soc Trans (2012) 1.02
The role of ubiquitylation in signaling by growth factors: implications to cancer. Semin Cancer Biol (2003) 1.01
Fluorescence lifetime endoscopy using TCSPC for the measurement of FRET in live cells. Opt Express (2010) 1.01
From autoinhibition to inhibition in trans: the Raf-1 regulatory domain inhibits Rok-alpha kinase activity. J Cell Biol (2009) 1.01
c-Cbl is a critical modulator of the Ron tyrosine kinase receptor. Oncogene (2003) 1.00
Negative regulation of receptor tyrosine kinases: unexpected links to c-Cbl and receptor ubiquitylation. Cell Res (2005) 0.98
How Förster resonance energy transfer imaging improves the understanding of protein interaction networks in cancer biology. Chemphyschem (2011) 0.98
The locus of microRNA-10b: a critical target for breast cancer insurgence and dissemination. Cell Cycle (2013) 0.96
Hsp90 increases LIM kinase activity by promoting its homo-dimerization. FASEB J (2006) 0.96
Monoubiquitylation: a recurrent theme in membrane protein transport. Isr Med Assoc J (2006) 0.95
Cancer therapeutic antibodies come of age: targeting minimal residual disease. Mol Oncol (2007) 0.95
Context-specific microRNA analysis: identification of functional microRNAs and their mRNA targets. Nucleic Acids Res (2012) 0.92
Signal transduction: molecular ticket to enter cells. Nature (2002) 0.92
Understanding micrometastatic disease and Anoikis resistance in ewing family of tumors and osteosarcoma. Oncologist (2010) 0.92
DART: Denoising Algorithm based on Relevance network Topology improves molecular pathway activity inference. BMC Bioinformatics (2011) 0.91
3D super-resolution imaging with blinking quantum dots. Nano Lett (2013) 0.90
Consistency test of the cell cycle: roles for p53 and EGR1. Cancer Res (2012) 0.90
A whole-body dual-modality radionuclide optical strategy for preclinical imaging of metastasis and heterogeneous treatment response in different microenvironments. J Nucl Med (2014) 0.90
A multi-functional imaging approach to high-content protein interaction screening. PLoS One (2012) 0.90
Geldanamycins trigger a novel Ron degradative pathway, hampering oncogenic signaling. J Biol Chem (2006) 0.90
Phosphorylation of carboxyl-terminal tyrosines modulates the specificity of Sprouty-2 inhibition of different signaling pathways. J Biol Chem (2005) 0.89
NMR metabolomics of MTLn3E breast cancer cells identifies a role for CXCR4 in lipid and choline regulation. J Proteome Res (2012) 0.88